Palisade Bio, Inc. (PALI)

Market Cap	75.57M
Revenue (ttm)	250,000
Net Income (ttm)	-12.32M
Shares Out	12.13M
EPS (ttm)	-27.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	70,139
Open	6.10
Previous Close	6.35
Day's Range	5.72 - 6.40
52-Week Range	3.82 - 36.60
Beta	1.46
Analysts	Strong Buy
Price Target	131.25 (+2,006.74%)
Earnings Date	May 10, 2024

About PALI

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: PALI

Analyst Forecast

According to 2 analysts, the average rating for PALI stock is "Strong Buy." The 12-month stock price forecast is $131.25, which is an increase of 2,006.74% from the latest price.

Price Target

$131.25

(2,006.74% upside)

Analyst Consensus: Strong Buy